Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place from November 6-10, 2024, in Houston, Texas. “Presenting our latest research provides an important platform to highlight Tempus’ advancements in applying AI and data to drive immunotherapy innovation,” said Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus. “We are committed to collaborating with the oncology community to share insights that can accelerate the development of more personalized, effective therapies and ultimately improve patient outcomes.”
Key highlights from Tempus’ poster presentations include:
Poster Presentation (#188): Clinical Validation of a Multi-Omic Algorithm for Stratifying Outcomes in Metastatic Cancer Patients Treated with Immune Checkpoint Inhibitors
Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. – 8:30 p.m. CT
Location: George R. Brown Convention Center; Exhibit Halls AB
Overview: This study focuses on predicting patient outcomes to immune checkpoint inhibitors (ICIs) by developing an integrated DNA/RNA biomarker, the Immune Profile Score (IPS). Using a de-identified pan-cancer cohort from Tempus’ multimodal real-world database, researchers validated that IPS status can stratify patient cohorts and predict responses to ICI treatment.
Poster Presentation (#1352): Impact of CT Imaging Timing on the Cost-Effectiveness of a Molecular Biomarker for Immunotherapy Treatment Response Monitoring
Session Date & Time: Saturday, November 9, 2024; 9:00 a.m. – 8:30 p.m. CT
Location: George R. Brown Convention Center; Exhibit Halls AB
Overview: This study modeled how the timing of CT imaging impacts the clinical utility and cost-effectiveness of a molecular biomarker for monitoring treatment responses in patients receiving immune checkpoint inhibitors (ICIs). The study found that combining the molecular biomarker with CT imaging resulted in cost savings and better management of inappropriate therapy, with the most benefit observed in small cell lung cancer (SCLC) treated with ICI-chemotherapy.
